KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Goodwill (2016 - 2022)

Historic Goodwill for Nektar Therapeutics (NKTR) over the last 13 years, with Q4 2022 value amounting to $76.5 million.

  • Nektar Therapeutics' Goodwill changed 0.0% to $76.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was $76.5 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $76.5 million for FY2022, which is 0.0% changed from last year.
  • Per Nektar Therapeutics' latest filing, its Goodwill stood at $76.5 million for Q4 2022, which was down 0.0% from $76.5 million recorded in Q3 2022.
  • In the past 5 years, Nektar Therapeutics' Goodwill registered a high of $76.5 million during Q1 2018, and its lowest value of $76.5 million during Q1 2018.
  • Moreover, its 5-year median value for Goodwill was $76.5 million (2018), whereas its average is $76.5 million.
  • Examining YoY changes over the last 5 years, Nektar Therapeutics' Goodwill showed a top increase of 0.0% in 2018 and a maximum decrease of 0.0% in 2018.
  • Nektar Therapeutics' Goodwill (Quarter) stood at $76.5 million in 2018, then changed by 0.0% to $76.5 million in 2019, then changed by 0.0% to $76.5 million in 2020, then changed by 0.0% to $76.5 million in 2021, then changed by 0.0% to $76.5 million in 2022.
  • Its last three reported values are $76.5 million in Q4 2022, $76.5 million for Q3 2022, and $76.5 million during Q2 2022.